Positive trial results for Alzheimer's drug Xanamem

Thursday, 28 April, 2022

Positive trial results for Alzheimer's drug Xanamem

Actinogen Medical has announced positive results for its lead drug Xanamem, reporting that it has demonstrated improved attention and working memory.

The Xanamem low dose-ranging trial was conducted in a population of 107 healthy, cognitively normal older adults aged 50–80 years, with a mean age of 64 years and a gender ratio of one male to two females. Trial participants were randomised to receive either 10 or 5 mg doses of Xanamem or a matching placebo for a six-week treatment period.

In a release to the ASX, Actinogen’s CEO Dr Steven Gourlay said, “We are excited to see the positive clinical data for these lower Xanamem dose levels. Xanamem has the potential to be a novel daily oral therapy for Alzheimer’s Disease and other conditions that could be safely used alone or in combination with other therapies. Our future clinical trials will evaluate if Xanamem can make a significant improvement in the lives of patients and their families living with serious neurological conditions.”

It is the second trial conducted by Actinogen that has shown positive results for the potential treatment of Alzheimer’s by Actinogen’s lead drug Xanamem moving the Aussie biotech a big step closer to a groundbreaking treatment of a condition that impacts millions worldwide.

Actinogen will now review detailed results of the Xanamem trial with academic and industry experts as it finalises the design of its next Alzheimer’s disease program trial. Detailed results will be published at a future scientific congress and in a peer-reviewed journal.

Image credit: ©stock.adobe.com/au/Andrea Danti

Related News

Pitfalls of high-risk prescribing

For many aged 65 years and older, good health is only achievable with the help of prescription...

Cluster trial to bring together over-65s and preschoolers

The trial will evaluate the potential for community intergenerational practice to reduce frailty...

Animations to help prevent dementia in CALD communities

The National Ageing Research Institute has launched the next phase of its Moving Pictures project...

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd